24/7 Emergency & General Advisory
π¨ 24/7 Medical Emergency
Non-Emergency Advisory
10:00 AM β 6:00 PM, MonβSat
For appointments & general queries.
Join our healthcare community
Stay updated with our latest healthcare news and your appointments.
Explore Familial Alzheimer's Disease (FAD), a rare, inherited form of early-onset dementia. Learn about its genetic causes, early symptoms, diagnosis, and current treatment approaches. Understand the critical role of family history and genetic testing in managing this challenging neurological condition.
Alzheimer's disease is a progressive neurodegenerative disorder that primarily affects memory, thinking, and behavior. While most cases of Alzheimer's disease are sporadic, meaning they occur without a clear genetic pattern, a small percentage are classified as Familial Alzheimer's Disease (FAD). FAD is a rare, inherited form of the disease that typically has an early onset, often before the age of 65, and sometimes even in the 30s or 40s. Understanding FAD is crucial for individuals with a family history of early-onset dementia, as it carries a significant genetic component that differentiates it from the more common late-onset sporadic Alzheimer's.
Unlike sporadic Alzheimer's, which is thought to result from a complex interplay of genetic, lifestyle, and environmental factors, FAD is directly caused by specific genetic mutations passed down through families. This article will delve into the symptoms, causes, diagnostic approaches, treatment options, and considerations for individuals and families affected by this devastating condition, providing a comprehensive overview to help navigate its complexities.
The symptoms of Familial Alzheimer's Disease are generally similar to those of sporadic Alzheimer's, but their early onset is a key distinguishing factor. The progression of symptoms can also be more rapid in FAD cases. Recognizing these signs early is vital for timely diagnosis and management.
As FAD advances, cognitive decline becomes more pronounced, and individuals may require significant assistance with daily activities.
The early onset and often aggressive progression of FAD symptoms place a unique burden on affected individuals and their families, necessitating early recognition and proactive management strategies.
Familial Alzheimer's Disease is caused by specific, inherited genetic mutations. It is an autosomal dominant disorder, meaning that a person needs to inherit only one copy of the mutated gene from a parent to develop the disease. If a parent has FAD, there is a 50% chance that each child will inherit the mutated gene and subsequently develop the disease.
The vast majority of FAD cases are linked to mutations in one of three genes:
The APP gene, located on chromosome 21, provides instructions for making the amyloid precursor protein. This protein is normally processed in the body, but mutations in the APP gene can lead to its abnormal cleavage, resulting in the overproduction or altered processing of beta-amyloid peptides. These peptides are sticky and tend to clump together, forming plaques in the brain, which are a hallmark pathological feature of Alzheimer's disease.
The PSEN1 gene, located on chromosome 14, provides instructions for making the presenilin 1 protein, a component of the gamma-secretase complex. This complex is crucial for cleaving various proteins, including APP. Mutations in PSEN1 are the most common cause of FAD, accounting for up to 70-80% of cases. These mutations alter the function of gamma-secretase, leading to increased production of the toxic AΞ²42 form of beta-amyloid, which readily aggregates into plaques.
The PSEN2 gene, located on chromosome 1, provides instructions for making the presenilin 2 protein, which is functionally similar to presenilin 1. Mutations in PSEN2 are a much rarer cause of FAD, accounting for less than 5% of cases. Like PSEN1 mutations, PSEN2 mutations also lead to altered processing of APP and an increased production of AΞ²42, contributing to amyloid plaque formation.
These genetic mutations lead to an accumulation of abnormal beta-amyloid protein in the brain, triggering a cascade of events that includes the formation of neurofibrillary tangles (composed of tau protein), inflammation, and neuronal cell death. This progressive damage ultimately results in the cognitive decline characteristic of Alzheimer's disease.

Can a simple blood draw really predict dementia decades before memory problems start? In 2026, several major studies said yes β one found a protein called p-tau217 predicted risk up to 25 years ahead in women, while another found a 78% risk of cognitive impairment within 10 years in people with the
July 23, 2026

Learn about Parkinson's disease symptoms, causes, stages, and treatment options. A complete guide for patients and caregivers in simple language.
June 13, 2026
Seeking a brain specialist in Kamarhati? Doctar connects you with leading neurologists and neurosurgeons for expert care. Book appointments now.
May 20, 2026